751 related articles for article (PubMed ID: 28086946)
1. MiR-1307 promotes ovarian cancer cell chemoresistance by targeting the ING5 expression.
Chen WT; Yang YJ; Zhang ZD; An Q; Li N; Liu W; Yang B
J Ovarian Res; 2017 Jan; 10(1):1. PubMed ID: 28086946
[TBL] [Abstract][Full Text] [Related]
2. MicroRNA-133b targets glutathione S-transferase π expression to increase ovarian cancer cell sensitivity to chemotherapy drugs.
Chen S; Jiao JW; Sun KX; Zong ZH; Zhao Y
Drug Des Devel Ther; 2015; 9():5225-35. PubMed ID: 26396496
[TBL] [Abstract][Full Text] [Related]
3. miR-218 targets survivin and regulates resistance to chemotherapeutics in breast cancer.
Hu Y; Xu K; Yagüe E
Breast Cancer Res Treat; 2015 Jun; 151(2):269-80. PubMed ID: 25900794
[TBL] [Abstract][Full Text] [Related]
4. The miR-193a-3p-regulated ING5 gene activates the DNA damage response pathway and inhibits multi-chemoresistance in bladder cancer.
Li Y; Deng H; Lv L; Zhang C; Qian L; Xiao J; Zhao W; Liu Q; Zhang D; Wang Y; Yan J; Zhang H; He Y; Zhu J
Oncotarget; 2015 Apr; 6(12):10195-206. PubMed ID: 25991669
[TBL] [Abstract][Full Text] [Related]
5. Upregulated in Hepatitis B virus-associated hepatocellular carcinoma cells, miR-331-3p promotes proliferation of hepatocellular carcinoma cells by targeting ING5.
Cao Y; Chen J; Wang D; Peng H; Tan X; Xiong D; Huang A; Tang H
Oncotarget; 2015 Nov; 6(35):38093-106. PubMed ID: 26497554
[TBL] [Abstract][Full Text] [Related]
6. ING5 suppresses breast cancer progression and is regulated by miR-24.
Cui S; Liao X; Ye C; Yin X; Liu M; Hong Y; Yu M; Liu Y; Liang H; Zhang CY; Chen X
Mol Cancer; 2017 May; 16(1):89. PubMed ID: 28490335
[TBL] [Abstract][Full Text] [Related]
7. Downregulation of miR-130a contributes to cisplatin resistance in ovarian cancer cells by targeting X-linked inhibitor of apoptosis (XIAP) directly.
Zhang X; Huang L; Zhao Y; Tan W
Acta Biochim Biophys Sin (Shanghai); 2013 Dec; 45(12):995-1001. PubMed ID: 24145606
[TBL] [Abstract][Full Text] [Related]
8. MicroRNA-34a Attenuates Paclitaxel Resistance in Prostate Cancer Cells via Direct Suppression of JAG1/Notch1 Axis.
Liu X; Luo X; Wu Y; Xia D; Chen W; Fang Z; Deng J; Hao Y; Yang X; Zhang T; Zhou L; Wu Y; Wang Q; Xu J; Hu X; Li L
Cell Physiol Biochem; 2018; 50(1):261-276. PubMed ID: 30282072
[TBL] [Abstract][Full Text] [Related]
9. MicroRNA-873 mediates multidrug resistance in ovarian cancer cells by targeting ABCB1.
Wu DD; Li XS; Meng XN; Yan J; Zong ZH
Tumour Biol; 2016 Aug; 37(8):10499-506. PubMed ID: 26850595
[TBL] [Abstract][Full Text] [Related]
10. MicroRNA-136 inhibits cancer stem cell activity and enhances the anti-tumor effect of paclitaxel against chemoresistant ovarian cancer cells by targeting Notch3.
Jeong JY; Kang H; Kim TH; Kim G; Heo JH; Kwon AY; Kim S; Jung SG; An HJ
Cancer Lett; 2017 Feb; 386():168-178. PubMed ID: 27887917
[TBL] [Abstract][Full Text] [Related]
11. Long Non-coding RNA CCAT1 Sponges miR-454 to Promote Chemoresistance of Ovarian Cancer Cells to Cisplatin by Regulation of Surviving.
Wang DY; Li N; Cui YL
Cancer Res Treat; 2020 Jul; 52(3):798-814. PubMed ID: 32124583
[TBL] [Abstract][Full Text] [Related]
12. miR-186 regulates chemo-sensitivity to paclitaxel via targeting MAPT in non-small cell lung cancer (NSCLC).
Ye J; Zhang Z; Sun L; Fang Y; Xu X; Zhou G
Mol Biosyst; 2016 Oct; 12(11):3417-3424. PubMed ID: 27714074
[TBL] [Abstract][Full Text] [Related]
13. ING5 suppresses proliferation, apoptosis, migration and invasion, and induces autophagy and differentiation of gastric cancer cells: a good marker for carcinogenesis and subsequent progression.
Gou WF; Shen DF; Yang XF; Zhao S; Liu YP; Sun HZ; Su RJ; Luo JS; Zheng HC
Oncotarget; 2015 Aug; 6(23):19552-79. PubMed ID: 25980581
[TBL] [Abstract][Full Text] [Related]
14. MicroRNA-630 inhibitor sensitizes chemoresistant ovarian cancer to chemotherapy by enhancing apoptosis.
Eoh KJ; Lee SH; Kim HJ; Lee JY; Kim S; Kim SW; Kim YT; Nam EJ
Biochem Biophys Res Commun; 2018 Mar; 497(2):513-520. PubMed ID: 29452092
[TBL] [Abstract][Full Text] [Related]
15. The down-regulated ING5 expression in lung cancer: a potential target of gene therapy.
Zhao S; Yang XF; Shen DF; Gao Y; Shi S; Wu JC; Liu HX; Sun HZ; Su RJ; Zheng HC
Oncotarget; 2016 Aug; 7(34):54596-54615. PubMed ID: 27409347
[TBL] [Abstract][Full Text] [Related]
16. MiR-27a modulates MDR1/P-glycoprotein expression by targeting HIPK2 in human ovarian cancer cells.
Li Z; Hu S; Wang J; Cai J; Xiao L; Yu L; Wang Z
Gynecol Oncol; 2010 Oct; 119(1):125-30. PubMed ID: 20624637
[TBL] [Abstract][Full Text] [Related]
17. Methylation-associated Has-miR-9 deregulation in paclitaxel- resistant epithelial ovarian carcinoma.
Li X; Pan Q; Wan X; Mao Y; Lu W; Xie X; Cheng X
BMC Cancer; 2015 Jul; 15():509. PubMed ID: 26152689
[TBL] [Abstract][Full Text] [Related]
18. MiR-216b increases cisplatin sensitivity in ovarian cancer cells by targeting PARP1.
Liu Y; Niu Z; Lin X; Tian Y
Cancer Gene Ther; 2017 May; 24(5):208-214. PubMed ID: 28281524
[TBL] [Abstract][Full Text] [Related]
19. Down-regulated expression of miR-134 contributes to paclitaxel resistance in human ovarian cancer cells.
Shuang T; Wang M; Shi C; Zhou Y; Wang D
FEBS Lett; 2015 Oct; 589(20 Pt B):3154-64. PubMed ID: 26363097
[TBL] [Abstract][Full Text] [Related]
20. HDAC1 Silencing in Ovarian Cancer Enhances the Chemotherapy Response.
Liu X; Yu Y; Zhang J; Lu C; Wang L; Liu P; Song H
Cell Physiol Biochem; 2018; 48(4):1505-1518. PubMed ID: 30071534
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
